Atherosclerosis and Lipoproteins |
From the Area of Cardiovascular Pathophysiology, Centre for Applied Medical Research (G.Z., G.S.J., M.U.M., A.F., J.D.), and the Departments of Internal Medicine (O.B.) and Cardiology and Cardiovascular Surgery (J.D.), University Clinic, School of Medicine, University of Navarra, Pamplona, Spain.
Correspondence to Dr Guillermo Zalba, Área de Fisiopatología Cardiovascular, Centro de Investigación Médica Aplicada, Avda Pío XII 55, 31008 Pamplona, Spain. E-mail gzalba{at}unav.es
| Abstract |
|---|
|
|
|---|
Methods and Results NADPH oxidasemediated superoxide production was determined by a chemiluminescence assay using lucigenin and associated with IMT for 184 asymptomatic subjects free of overt clinical atherosclerotic disease. Compared with individuals in the lowest tertile of superoxide production, those in the upper tertile (>20 counts/sec) showed significantly higher IMT (P<0.05). In correlation analysis, a positive relationship was found between superoxide production and carotid IMT. Superoxide production also correlated positively (P<0.05) with body mass index (BMI). In multivariate analysis, the association of superoxide production with carotid IMT remained significant after adjustment for age, sex, systolic blood pressure, BMI, triglycerides, glucose, and smoking.
Conclusions In a population sample of adults without clinically overt atherosclerotic disease, increased NADPH oxidase activity was associated with enhanced carotid IMT, suggesting a relationship between phagocytic NADPH oxidasemediated oxidative stress and the development of atherosclerosis.
Oxidative stress plays a critical role in the pathogenesis of atherosclerosis. In a population sample of 184 adults without clinically overt atherosclerotic disease, increased NADPH oxidasederived superoxide production from phagocytic cells associated with enhanced carotid intima-media thickness, thus suggesting a relationship between phagocytic NADPH oxidase and the development of atherosclerosis.
Key Words: atherosclerosis carotid arteries intima-media thickness NADPH oxidase superoxide
| Introduction |
|---|
|
|
|---|
The NADPH oxidase systems, which constitute the most important source of superoxide (O2·) in the vessel wall, are present in endothelial cells, VSMCs, and fibroblasts.4 The structure of vascular NADPH oxidases is similar, although differs structurally and biochemically, from the phagocytic NADPH oxidase, an oxidase originally identified in the defense against exogenous microorganisms. The phagocytic oxidase is a membrane-bound enzyme that catalyzes the single electron reduction of molecular oxygen to form O2·. It consists of a membrane-associated cytochrome b558, and 3 cytosolic components p47phox, p67phox, and rac1/2. Cytochrome b558 comprises a large subunit, gp91phox (also called Nox2), and a smaller subunit, p22phox, and it functions as the final electron transporter from NADPH to molecular oxygen.5 Although intensive investigations have been conducted to identify the vascular NADPH oxidases, their molecular characterization still remains unclear. In the past years, 2 novel gp91phox/Nox2 homologues, Nox1 and Nox4, were identified in VSMCs and represent functional oxidases.69 More recently, it has been shown that Nox4 functions as the major catalytic component of endothelial NADPH oxidase.10
In the past years, several works have demonstrated a key role of vascular NADPH oxidase isoforms in the development of human atherosclerosis.1115 Interestingly, it has been also reported the contributing role of the infiltrated monocyte NADPH oxidase in the development of the atherosclerotic lesion.1315 It is traditionally accepted that ROS generation from infiltrated monocytes contributes to atherosclerotic lesion formation.16 With this background, it might be suggested that besides a major role of vascular NADPH oxidases, phagocytic NADPH oxidase could play a significant role in the development and progression of atherosclerotic lesion.
Available evidence substantiates that carotid intima-media thickness (IMT), as measured by B-mode ultrasound, correlates with the presence of coronary atherosclerosis17 and represents an independent risk factor for atherothrombotic events (ie, coronary heart disease events, stroke, and transient cerebral ischemia).1820 Thus, carotid ultrasound examination and IMT measurement can provide a useful surrogate marker for atherosclerotic disease.21 We have hypothesized that an association may exist between phagocytic NADPH oxidase activity and atherosclerosis in asymptomatic subjects. To test this hypothesis, we have investigated the relationship between NADPH oxidasemediated O2· production in phagocytic cells and carotid IMT in middle-aged adults with no past or current medical history of atherosclerotic disease.
| Patients and Methods |
|---|
|
|
|---|
Assessment of Cardiovascular Risk Factors
The presence of cardiovascular risk factors such as diabetes mellitus, arterial hypertension, dyslipidemia, obesity, and smoking habits were also assessed (available online at http://atvb.ahajournals.org).
Determination of O2· Production
We measured O2· production in peripheral mononuclear cells (lymphocytes and monocytes) isolated from blood samples with Lymphoprep, in response to stimulation with phorbol myristate acetate (PMA) (3.2x106 mol/L), and using 10 µmol/L lucigenin by a chemiluminescence method as previously described.22 In some experiments, the effect of 5 µmol/L diphenylene iodonium, a flavoprotein inhibitor, and 2.5x103 mol/L apocynin, a specific intracellular inhibitor of NADPH oxidase assembly, were studied. To verify the specificity of the lucigenin assay for O2· generation in our model, the effect of superoxide dismutase (SOD) 10 000 U/mL, an enzymatic scavenger of O2·, was also examined. Although lucigenin concentration was low enough to avoid auto-oxidation, the measurements were validated against an independent measurement of O2· production using SOD-inhibitable ferricytochrome c reduction (available online). The measurement of O2· production using SOD-inhibitable ferricytochrome c reduction closely correlated with lucigenin measurements (Figure I, available online at http://atvb.ahajournals.org). In some subjects, phagocytic O2· production was evaluated in response to angiotensin II and endothelin 1.
Measurement of Carotid IMT
Ultrasonography of the common carotid arteries was performed with a 5- to 12-MHz linear-array transducer (ATL 500 HDI). The measurement of IMT was made 1 cm proximal to the carotid bulb of each common carotid artery at plaque-free sites. For each individual, the IMT was determined as the average of near wall and far wall measurements of each common carotid artery. Subjects were examined by the same 2 certified sonographers blinded to all clinical information. The reproducibility of IMT measurements between and within sonographers had previously been checked in individuals who returned 2 weeks later for a second examination.23 The intraobserver and interobserver coefficients of variation were 5% and 10%, respectively.
Statistical Analysis
Data are expressed as mean±SEM. Differences in the baseline characteristics of subjects classified according to tertiles of O2· production, in the O2· production of subjects classified according to quartiles of carotid IMT, and in the O2· production of phagocytes in response to different agonists were evaluated by ANOVA followed by Tukey B post hoc test. The
2 analysis was used to search for differences for qualitative variables. Pearson correlation test was used to assess correlations between O2· production and all continuous variables. Multivariate linear regression analysis was performed to evaluate factors related to carotid IMT and the possibility of interactions. All variables that were significantly correlated with carotid IMT in the univariate analysis were included in the model. The statistical analysis was performed with SPSS 11.0 for Windows.
| Results |
|---|
|
|
|---|
Angiotensin II (0.1 µmol/L) and endothelin 1 (0.01 µmol/L) significantly stimulated the phagocytic NADPH oxidase mediated O2· production (basal, 1.00±0.04 counts/sec; angiotensin II, 1.78±0.09 counts/sec; endothelin 1, 1.65±0.06 counts/sec) (Figure 1).
|
O2· Production: IMT Associations
The mean level of phagocytic O2· production was 18.6 counts/sec (range, 0.1 to 130 counts/sec). Table 1 shows the demographic and clinical characteristics of subjects stratified by tertiles of phagocytic NADPH oxidasemediated O2· production. Subjects in the upper tertile of phagocytic O2· production exhibited an increased carotid IMT compared with subjects in the medium and the lowest tertiles (P<0.05). Moreover, subjects in the upper tertile also had higher systolic blood pressure, body mass index, glucose, and triglycerides than subjects in the lowest tertile (P<0.05). The percentage of men was also significantly elevated in the upper tertile. No differences among tertiles were found for the remaining characteristics tested.
|
There was a significant positive bivariate correlation between phagocytic O2· production and carotid IMT (r=0.293, P<0.001) in all the subjects. As shown in Table 2, the association between the 2 parameters remained highly significant (r=0.248, P=0.001) after controlling for age and sex. Phagocytic O2· production was also significantly associated with triglycerides (r=0.159, P<0.05) and body mass index (r=0.202, P<0.01), with the latter also remaining statistically significant after controlling for age and sex.
|
Carotid IMT significantly correlated with age (r=0.404, P<0.001), systolic blood pressure (r=0.159, P<0.05), glucose (r=0.278, P<0.001), body mass index (r=0.240, P<0.005), and triglycerides (r=0.169, P<0.05), with the 3 latter also remaining statistically significant after controlling for age and sex (Table 3).
|
Because of the associations found of phagocytic O2· production and IMT with some cardiovascular risk factors, a further multivariate analysis was performed to assess the relationship between phagocytic O2· production and carotid IMT after adjusting for these potential confounding factors (Table 4). A significant association between phagocytic O2· production and IMT (P=0.001) remained after adjusting for all the potential confounding factors, with the O2· production explaining up to 14.3% of the IMT variance after adjusting for the effects of common risk factors. Besides this association, we found that age also associated with IMT (P=0.001) independently of O2· production.
|
The distribution of O2· production by quartiles of carotid IMT showed a significant difference in O2· production (P<0.05) between the quartiles of IMT (Figure 2); moreover, O2· production was significantly increased in the third and the fourth quartiles compared with the first (quartile 1: 13.6±1.5 counts/sec, N=43; quartile 2: 17.4±2.1 counts/sec, N=49; quartile 3: 20.1±2.5 counts/sec, N=45; quartile 4: 23.1±3.9 counts/sec, N=47).
|
| Discussion |
|---|
|
|
|---|
Carotid IMT indicates the status of the vascular wall and is a useful method to study atherosclerotic disease. Carotid IMT has been correlated with cardiovascular risk factors, such as age, hypertension, hypercholesterolemia, and smoking, associated with the development of atherosclerosis in any vascular bed.21 Available evidence substantiates that carotid IMT correlates positively with coronary and peripheral atherosclerosis. Craven et al17 demonstrated that a measure of carotid IMT was strongly and independently associated with coronary artery disease in patients older than 50 years. Besides, carotid IMT represents an independent risk factor for atherothrombotic events.1820 Moreover, an increase of 1 standard deviation in IMT measurement was associated with a 1.36 relative risk for the combined end point of myocardial infarction or stroke.25 Taken together, these studies demonstrate that carotid IMT correlates with atherosclerosis and represents an independent risk factor for coronary heart disease events, stroke, and transient cerebral ischemia, thus providing a useful surrogate marker for atherosclerotic disease.21
The NADPH oxidase systems constitute the most important source of O2· in the cells of the vessel wall.4 Vascular NADPH oxidase isoforms are similar, although they differ from the phagocytic NADPH oxidase system. In the past years, it has been reported a significant involvement of vascular NADPH oxidases in the pathophysiology of vascular wall. Overexpression of Nox homologues in fibroblasts suggests that Nox1 has mitogenic activity and is growth-promoting,6 whereas Nox4 decreased the rate of cell proliferation and is implicated in cellular senescence.7 In VSMC, Nox1 is upregulated by proliferative stimuli, such as angiotensin II and platelet-derived growth factor, whereas Nox4 is downregulated by these agonists26 and by proinflammatory mediators, such as IL-1ß and thrombin.27 In endothelial cells, Nox4 is upregulated by serum removal and downregulated by addition of serum.10 In a model of restenosis, the expression of Nox1, Nox2, and p22phox is elevated early after injury, whereas Nox4 increases later,28 coinciding with a reduction in the rate of VSMC proliferation. Inhibition of Nox2-dependent NADPH oxidase suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery.29 Collectively, Nox1 and Nox2 are involved in acute response to injury or to proliferative stimulation, whereas Nox4 is involved in maintaining the quiescent phenotype. In contrast to Nox2 and Nox4, the importance of Nox1 in human vessels is less clear, because very low levels of expression have been detected in coronary arteries,14 and in mammary artery and saphenous vein.9
During the past decade, it has been shown an essential role of NADPH oxidases in the development of atherosclerosis. Guzik et al11 showed that vascular NADPH oxidases are major sources of O2· in human vessels and showed an association between enzymatic activity and clinical risk factors in atherosclerosis. Besides, this increase in NADPH oxidase activity impaired endothelium-dependent vasodilation in atherosclerotic patients. Azumi et al12 found that the severity of atherosclerotic lesion correlated with p22phox overexpression in coronary arteries. Sorescu et al14 demonstrated that Nox4 was increased in early lesions during the atheroma stage of the plaque and decreased in more advanced stages of lesions in coronary arteries, whereas Nox2 and p22phox were greatly increased along the progression of human atherosclerotic plaques, thus suggesting a possible causal link between the classic NADPH oxidase and the development of lesions. Interestingly, the contribution of Nox2 to lesion progression was caused almost entirely by infiltrated monocytes.13,14 In fact, preactivated monocytes exhibit higher cytokine production and greater adherence to the vascular wall,30,31 and play a role in the oxidative stress-mediated pathogenesis of atherosclerosis.32 Moreover, NADPH oxidasederived O2· production from infiltrated monocytes may contribute to atherosclerotic lesion formation.16 Thus, our study showing a substantial increase in NADPH oxidasedependent O2· formation in phagocytic cells from subjects with higher values of IMT adds new insights into the contributing role of the phagocytic NADPH oxidase system in the initiation and progression of human atherosclerosis. The significance of our data are underlined by a study showing that ROS production spatially associated with the distribution of p22 phox and oxidized low-density lipoprotein in atherosclerotic human coronary arteries.15 Although VSMCs and fibroblasts participated in ROS generation, these species were mainly generated by infiltrated inflammatory cells.15 Moreover, ROS production was significantly higher in unstable versus stable angina pectoris, which suggests that ROS might also modulate plaque stability.15 Collectively, these studies support the possibility that both phagocytic and vascular NADPH oxidase systems may play an essential role in the development and progression of atherosclerotic lesion. This hypothesis is underlined by a genetic study showing that deletion of the NADPH oxidase subunit p47phox gene reduces the area of atherosclerosis in the descending aorta of apolipoprotein E/ knockout mice.33
Our findings showing that phagocytic NADPH oxidasedependent O2· production explained up to 14.3% of the carotid IMT variance after adjusting for the effect of common risk factors, suggest that vascular NADPH oxidase isoforms may be also participating in the atherosclerotic process.1115 Furthermore, we should take into account that several enzymatic origins have been proposed as sources of ROS in atherosclerotic process other than NADPH oxidases, such as lipoxygenase, xanthine oxidase, and nitric oxide synthase.34 It has also been highlighted the impact of age as a major determinant of carotid IMT.35 Likewise, the influence of age on carotid IMT was similarly strong (12.1%) in our survey, even after adjusting for phagocytic NADPH oxidasemediated O2· production.
An important number of potential stimulating factors of the NADPH oxidase system may be related to increased phagocytic O2· production in the setting of cardiovascular diseases. Several humoral factors, including angiotensin II, endothelin 1, and some cytokines, stimulate the phagocytic NADPH oxidase activity.3639 Likewise, our study reported that angiotensin II and endothelin 1 stimulated O2· production in phagocytic cells. In addition, several polymorphisms of CYBA, the human gene that encodes the p22phox subunit, play a functional role on the NADPH oxidase activity.22,40,41
Overall, our findings suggest that increased phagocytic NADPH oxidase activity may represent a potential indicator of oxidation occurring in the vascular wall of asymptomatic subjects. Because the present study does not provide direct evidence of the potential role of the vascular NADPH oxidase isoforms, it is important to point out that the increased phagocytic NADPH oxidasedependent O2· production might not necessarily be the main culprit of the increased carotid IMT but may be simply a harbinger of the activation of vascular NADPH oxidase isoforms. Moreover, our data showing that phagocytes respond to the same circulating factors that are also directly stimulating the vascular NADPH oxidase homologues lead us to consider the possibility that phagocytic NADPH oxidase activation might be the reflection of the oxidation occurring in the vasculature.
One limitation of the study is that the cross-sectional analysis and the small sample size restrict our interpretation of the results, which represent a potential bias for complex multifactorial analysis. Because few women and no elderly individuals were included, results cannot be extrapolated to such populations at risk of cardiovascular disease. Another limitation is the lack of standardized ultrasound protocols for the measurement and interpretation of carotid IMT.23 To obtain accurate measurements of carotid IMT, the same 2 certified sonographers performed ultrasound examination along our study. Finally, the unavailability of vascular tissue biopsies that would allow us to identify which NADPH oxidase system is in fact involved in the thickening of vascular wall constitutes another limitation.
In summary, we found that increased phagocytic NADPH oxidasedependent O2· production is associated with enhanced carotid IMT in subjects without clinically overt atherosclerotic disease. Because carotid IMT correlates with atherosclerosis, our study supports that activation of phagocytic NADPH oxidase significantly associates with the atherosclerotic process in these subjects. The relevance of our findings is underlined by the significant role that oxidative stress plays in the initiation, progression, and the end event of the atherosclerotic process.
| Acknowledgments |
|---|
Received December 1, 2004; accepted April 7, 2005.
| References |
|---|
|
|
|---|
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115126.
3. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003; 42: 10751081.
4. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res. 2000; 86: 494501.
5. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci. 2003; 28: 502508.[CrossRef][Medline] [Order article via Infotrieve]
6. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. Cell transformation by the superoxide-generating oxidase mox1. Nature. 1999; 401: 7982.[CrossRef][Medline] [Order article via Infotrieve]
7. Geiszt M, Kopp JB, Várnai P, Leto TL. Identification of Renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A. 2000; 97: 80108014.
8. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004; 24: 677683.
9. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol. 2004; 24: 16141620.
10. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004; 109: 227233.
11. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000; 86: E85E90.
12. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999; 100: 14941498.
13. Kalinina N, Agrotis A, Tararak E, Antropova Y, Kanellakis P, Ilyinskaya O, Quinn MT, Smirnov V, Bobik A. Cytochrome b558-dependent NAD(P)H oxidasephox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2002; 22: 20372043.
14. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002; 105: 14291435.
15. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris. Important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002; 22: 18381844.
16. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 2328.
17. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Crouse JR3rd. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation. 1990; 82: 12301242.
18. Bots ML, Hoes AW, Kondstaal PJ, Hofman A, Grobbe DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation. 1997; 96: 14321437.
19. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000; 151: 478487.
20. Longstreth WT Jr., Shemanski L, Lefkowitz D, OLeary DH, Polak JF, Wolfson SK Jr. Asymptomatic internal carotid artery stenosis defined by ultrasound and the risk of subsequent stroke in the elderly. The Cardiovascular Health Study. Stroke. 1998; 29: 23712376.
21. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004; 109 (Suppl IV): 2230.
22. San Jose G, Moreno MU, Olivan S, Beloqui O, Fortuno A, Diez J, Zalba G. Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension. 2004; 44: 163169.
23. Martínez-Vila E, Páramo JA, Beloqui O, Irimia P, Colina I, Monreal I, Benito A, Barba J, Zubieta JL, Diez J. Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects. Cerebrovasc Dis. 2003; 16: 356362.[CrossRef][Medline] [Order article via Infotrieve]
24. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994; 11: 95102.[Abstract]
25. OLeary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 1422.
26. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001; 88: 888894.
27. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res. 2005; 65: 495504.
28. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002; 22: 2127.
29. Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewski T, Pagano PJ. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003; 92: 637643.
30. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999; 34: 113117.
31. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens. 2002; 20: 593596.[CrossRef][Medline] [Order article via Infotrieve]
32. Dorffel Y, Franz S, Pruss A, Neumann G, Rohde W, Burmester GR, Scholze J. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis. 2001; 157: 151160.[CrossRef][Medline] [Order article via Infotrieve]
33. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(/) mice. J Clin Invest. 2001; 108: 15131522.[CrossRef][Medline] [Order article via Infotrieve]
34. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 2938.
35. OLeary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK Jr., Bommer W, Price TR, Gardin JM, Savage PJ. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke. 1992; 23: 17521760.
36. El Bekay R, Alvarez M, Monteseirin J, Alba G, Chacon P, Vega A, Martin-Nieto J, Jimenez J, Pintado E, Bedoya FJ, Sobrino F. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood. 2003; 102: 662671.
37. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003; 23: 776782.
38. Cassatella MA, Bazzoni F, Amezaga MA, Rossi F. Studies on the gene expression of several NADPH oxidase components. Biochem Soc Trans. 1991; 19: 6367.[Medline] [Order article via Infotrieve]
39. Fortuño A, Oliván S, Beloqui O, San José G, Moreno MU, Díez J, Zalba G. Association of increased phagocytic NADPH oxidasedependent superoxide production with diminished nitric oxide production in essential hypertension. J Hypertens. 2004; 22: 21692175.[CrossRef][Medline] [Order article via Infotrieve]
40. Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Diez J, Zalba G. Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Lett. 2003; 542: 2731.[CrossRef][Medline] [Order article via Infotrieve]
41. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Functional effect of the C242T polymorphism in the NADPH oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000; 102: 17441747.
This article has been cited by other articles:
![]() |
F. Violi, V. Sanguigni, R. Carnevale, A. Plebani, P. Rossi, A. Finocchi, C. Pignata, D. De Mattia, B. Martire, M. C. Pietrogrande, et al. Hereditary Deficiency of gp91phox Is Associated With Enhanced Arterial Dilatation: Results of a Multicenter Study Circulation, October 20, 2009; 120(16): 1616 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Martino, L. Loffredo, R. Carnevale, V. Sanguigni, E. Martino, E. Catasca, C. Zanoni, P. Pignatelli, and F. Violi Oxidative Stress Is Associated With Arterial Dysfunction and Enhanced Intima-Media Thickness in Children With Hypercholesterolemia: The Potential Role of Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Pediatrics, September 1, 2008; 122(3): e648 - e655. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zalba, A. Fortuno, J. Orbe, G. San Jose, M. U. Moreno, M. Belzunce, J. A. Rodriguez, O. Beloqui, J. A. Paramo, and J. Diez Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9: Implications for Human Atherosclerosis Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 587 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zalba, A. Fortuno, and J. Diez Oxidative stress and atherosclerosis in early chronic kidney disease Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2686 - 2690. [Full Text] [PDF] |
||||
![]() |
A. Fortuno, G. San Jose, M. U. Moreno, O. Beloqui, J. Diez, and G. Zalba Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome Diabetes, January 1, 2006; 55(1): 209 - 215. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |